Tickers

1. Composite Trajectory Verdict

All three financial statements carry roughly equal weight for SHC given its capital-intensive, regulated sterilization and lab services model where earnings quality, cash conversion for debt service, and balance sheet deleveraging are all critical to assessing trajectory.

Composite Trajectory: Improving

The composite assessment is driven by improving trends in cash generation and balance sheet strength, while earnings show a mixed annual pattern but clear recent acceleration. Annual operating cash flow swung from -$147.7M (2023) to $224.2M (2024) to $287.2M (2025), with capex declining each year (10-K 2025-12-31, Consolidated Statements of Cash Flows). The balance sheet shows equity rising from $404.9M to $606.0M and long-term debt falling from $2,208.1M to $2,126.7M over the same period (10-K 2025-12-31, Consolidated Balance Sheets; Note 9). GAAP net income dipped from $51.4M (2023) to $44.4M (2024) before jumping to $77.9M (2025), but quarterly data confirms momentum: Q2 2026 net income of $53.6M vs $8.0M in Q2 2025, and six-month 2026 net income of $80.2M vs a -$5.3M loss in the prior year (10-Q 2026-06-30, MD&A).

2. Red Flags

• Recurring "non-recurring" EO litigation costs: Professional fees for EO facilities were $45.3M (2023), $32.7M (2024), $46.2M (2025) plus settlement payments of $35.0M (2023 Georgia), $64.9M (2025 Illinois) (10-K 2025-12-31, MD&A; Consolidated Statements of Operations). These appear annually despite non-GAAP adjustments treating them as non-routine.
• Wide and persistent GAAP vs. non-GAAP gap: Adjusted Net Income exceeded GAAP net income by 3.1x in 2025 ($245.4M vs $77.9M), 4.5x in 2024 ($198.5M vs $44.4M) (10-K 2025-12-31, Non-GAAP Financial Measures reconciliation).
• High leverage despite improvement: Total debt of $2.13B vs equity of $606M (3.5x debt/equity) and GAAP operating income of ~$362M yielding ~1.7x interest coverage (10-K 2025-12-31, Consolidated Statements of Operations; Balance Sheets; Note 9).
• Growing valuation allowance on deferred tax assets: Increased from $125.4M (2023) to $160.6M (2024) to $172.3M (2025), primarily from U.S. interest expense limitation (10-K 2025-12-31, Schedule II; Note 10).
• Goodwill concentration: $1.1B goodwill represents 33.8% of total assets (10-K 2025-12-31, Critical Accounting Policies; Note 7).
• Nordion customer concentration: Two customers accounted for 34.8% and 11.0% of segment revenue in 2025 (10-K 2025-12-31, Note 21).
• Negative operating cash flow in 2023 driven by $407.7M Illinois EO litigation cash outflow (10-K 2025-12-31, Consolidated Statements of Cash Flows).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP net income declined 13.6% from $51.4M (2023) to $44.4M (2024) despite 4.9% revenue growth, then surged 75.6% to $77.9M (2025) on 5.7% revenue growth (10-K 2025-12-31, Consolidated Statements of Operations). Gross margin improved steadily: 55.0% (2023), 54.7% (2024), 55.5% (2025). SG&A grew 6.8% (2023-2024) and 4.2% (2024-2025), slower than revenue. Amortization of intangibles dropped 50.5% to $30.7M in 2025 as assets fully amortized (10-K 2025-12-31, MD&A). Interest expense fell 5.4% to $155.7M in 2025. Quarterly trends are strongly positive: Q2 2026 net income $53.6M vs $8.0M in Q2 2025; six-month 2026 $80.2M vs -$5.3M (10-Q 2026-06-30, MD&A). The mixed tag reflects the non-monotonic annual net income trend offset by improving margins and strong recent quarterly momentum.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Operating cash flow improved dramatically across three annual periods: -$147.7M (2023), $224.2M (2024), $287.2M (2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows). The 2023 outflow was dominated by a $407.7M Illinois EO litigation settlement payment; excluding that, operating cash flow would have been positive. Capital expenditures declined each year: $215.0M (2023), $179.1M (2024), $138.0M (2025), yielding implied free cash flow (operating minus capex) of -$362.7M, +$45.1M, +$149.2M respectively. Cash paid for interest decreased from $179.9M (2024) to $164.0M (2025) (10-K 2025-12-31, Supplemental Cash Flow Information). Quarterly cash flow statements were not fully provided in the 10-Q filings, preventing quarterly trend analysis.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total equity rose 49.7% from $404.9M (2024) to $606.0M (2025) driven by net income and $98.1M foreign currency translation gains (10-K 2025-12-31, Consolidated Balance Sheets; Consolidated Statements of Equity). Long-term debt declined 3.7% from $2,208.1M to $2,126.7M (10-K 2025-12-31, Note 9). Cash and equivalents increased 24.3% from $277.2M to $344.6M. The debt structure was repriced in September 2025 (Amendment No. 6), reducing the term loan spread to SOFR+2.50% and extending maturity to 2031, with a $75M principal paydown (10-K 2025-12-31, Note 9). The revolving credit facility was expanded to $600M and extended to 2030 (Amendment No. 5). Debt maturities are manageable at ~$14M/year through 2030 with a $2.1B bullet thereafter (10-K 2025-12-31, Note 9). Leverage metrics improved: debt-to-equity from 5.5x to 3.5x; Adjusted EBITDA/interest expense from 3.3x to 3.8x (10-K 2025-12-31, Non-GAAP Financial Measures; Consolidated Statements of Operations).

6. Data Gaps

• Quarterly cash flow statements for Q2 2026, Q1 2026, Q3 2025, Q2 2025 (10-Q filings truncated in provided documents)
• Standalone Q3 2025 and Q4 2025 income statements (only annual and six-month/Q2 2026 data available)
• Segment-level depreciation and amortization for quarterly periods
• Free cash flow for quarterly periods
• Full 10-Q financial statements for periods 2026-03-31, 2025-09-30, 2025-06-30 (only MD&A sections provided)